Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Promega Corporation

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Promega Corporation

Regulatory records
2
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 2 FDA records to the applicant name Promega Corporation. It includes 2 original PMA approvals. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Nov 5, 2025 to Sep 15, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code SFL appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P240026, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 2800 Woods Hollow Rd., Madison, WI, 53711. Recorded on P250046, decision dated Sep 15, 2026.

Changes described in PMA records

P250046: OncoMate MSI Dx Analysis System

The FDA database entry records an approval decision dated September 15, 2026, for the OncoMate® MSI Dx Analysis System from Promega Corporation. The device is classified as a nucleic acid based assay for microsatellite instability under product code SFL and specialty Medical Genetics. The statement describes a qualitative multiplex PCR test that detects mononucleotide deletions in five microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) using DNA from FFPE solid tumor tissue, with a matched normal specimen from the same individual obtained from FFPE tissue or whole blood.

The system is specified for use with the Applied Biosystems® 3500 Dx Genetic Analyzer and OncoMate® MSI Dx Analysis Software. The statement reports the intended use as a companion diagnostic to identify MSI-H patients with advanced solid tumor cancers eligible for treatment with KEYTRUDA® in accordance with the approved therapeutic product labeling. The entry does not include supplement type or supplement reason fields, so no information about a changed item or relationship to a prior PMA is present in the record.

FDA approval-order wording

Approval for the OncoMate MSI Dx Analysis System. The OncoMate MSI Dx Analysis System is a qualitative multiplex polymerase chain reaction (PCR) test intended to detect the deletion of mononucleotides in five microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) using DNA obtained from formalin-fixed, paraffin-embedded (FFPE) solid tumor tissue. The assay requires DNA from a matched normal specimen of the same individual, which may be obtained from FFPE tissue or whole blood. The OncoMate MSI Dx Analysis System is for use with the Applied Biosystems 3500 Dx Genetic Analyzer and OncoMate MSI Dx Analysis Software.The OncoMate MSI Dx Analysis System is intended for use as a companion diagnostic to identify MSI-H patients with advanced solid tumor cancers eligible for treatment with KEYTRUDA in accordance with the approved therapeutic product labeling.

Sep 15, 2026

P240026: OncoMate MSI Dx Analysis System

FDA’s recorded scope: Approval for the OncoMate MSI Dx Analysis System. The OncoMate MSI Dx Analysis System is a qualitative multiplex polymerase chain reaction (PCR) test intended to detect the deletion of mononucleotides in five microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) for the identification of microsatellite instability (MSI) using DNA obtained from formalin-fixed, paraffin-embedded (FFPE) endometrial carcinoma tissue specimens, and DNA isolated from matched normal FFPE specimen or whole blood. The OncoMate MSI Dx Analysis System is for use with the Applied Biosystems 3500 Dx Genetic Analyzer and OncoMate MSI Dx Analysis Software.The OncoMate MSI Dx Analysis System is indicated for use as a companion diagnostic test to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA (pembrolizumab) in combination with LENVIMA (lenvatinib) in accordance with the approved therapeutic product labeling.

Nov 5, 2025

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Promega CorporationPMA approvalSep 15, 2026FDA
Promega CorporationPMA approvalNov 5, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.